Screener
Arcus Biosciences RCUS Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Other noncurrent liabilities | 124 | 135 |
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 127.0 shares in 2026 and 125.3 shares in 2025 issued and outstanding | 2,169 | 2,116 |
| Accumulated deficit | (1,704) | (1,485) |
| Accumulated other comprehensive loss | (1) | — |
| Total stockholders’ equity | 464 | 631 |
| Total liabilities and stockholders’ equity | $924 | $1,139 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's common stock?
- Arcus Biosciences (RCUS) reported common stock of 400M in Q2 2026.
- How has Arcus Biosciences's common stock changed year-over-year?
- Arcus Biosciences's common stock decreased by 0.0% year-over-year, from 400M to 400M.
- What is the long-term trend for Arcus Biosciences's common stock?
- Over 5 years (2020 to 2025), Arcus Biosciences's common stock has grown at a 822.1% compound annual growth rate (CAGR), from 6K to 400M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Arcus Biosciences's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude